Stay updated on SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.

Latest updates to the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page
- Check3 days agoChange DetectedA government funding lapse notice is now displayed on the page, and the site revision tag has been updated to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check10 days agoChange DetectedGlossary visibility was added and QC-related labels were updated to show the new revision (v3.4.0), replacing the previous version and capitalization variants.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision: v3.3.4 replaces the previous v3.3.3 on the page; no substantive changes to study details or eligibility criteria are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check45 days agoChange DetectedA dedicated Locations section has been added listing sites by state (Arizona, Maryland, Oregon, Texas). The previous state-specific subsections were removed, indicating a reorganization of site listings.SummaryDifference0.5%

- Check74 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the page.SummaryDifference0.0%

- Check81 days agoChange DetectedA site-wide notice about a lapse in government funding and potential updates/response delays has been removed from the page. This change does not affect the trial details, eligibility criteria, or study results presented on the NCT03238027 page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.